Navigation Links
ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
Date:7/29/2008

LEUVEN, Belgium, July 30 /PRNewswire-FirstCall/ --

- Shares Acquired From Biggar Limited

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on eye disease, vascular disease and cancer, today announces that a group of private investors based in Belgium have together acquired an 8% stake in the Company. Their stake was purchased from Biggar Limited, a charitable foundation that is ThromboGenics largest shareholder. Biggar now holds a 9.8% stake in ThromboGenics following this transaction, and has informed the company that it intends to remain an important shareholder in ThromboGenics for the long term.

This transaction was managed by Petercam.

Prof. Desire Collen, Chairman and CEO of ThromboGenics, commenting on today's announcement, said: "We are very pleased that we have been able to attract such a group of high net worth individuals to become shareholders in ThromboGenics, particularly given their long term commitment to the Company. We are confident that we will be able to generate significant value for all our shareholders over the next several years based on the exciting prospects for microplasmin in the treatment of back of the eye disease, our other pipeline products, including TB-402 for deep vein thrombosis, as well as the significant potential that we see for TB-403 in the treatment of cancer, which was recently licensed to Roche."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
2. ThromboGenics N.V. - Business Update
3. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
4. ThromboGenics Announces 2007 Full Year Results
5. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
8. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
9. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
10. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... RARITAN, N.J. , May 30, ... two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show ... anti-CD38 monoclonal antibody – achieved an overall response ... as assessed by an independent review committee, in ... was consistent among the pre-specified subgroups based on ...
(Date:5/29/2015)... HILL, N.C. , May 29, 2015 /PRNewswire/ ... medical affairs function into roles involving clinical development, ... As its responsibilities have grown, Medical Affairs has ... function as a global group. And while its ... find it challenging to identify strong performance metrics ...
(Date:5/29/2015)... -- BerGenBio AS ("BerGenBio" or the "Company"), ... on the latest data on BGB324, the Company,s first-in-class, ... kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in ... with the 2015 American Society of Clinical Oncology (ASCO) ... 29 - June 2, 2015. The abstract ...
(Date:5/29/2015)... May 29, 2015 The Academy of ... thirteen high school graduates from across the nation. , ... to award qualified AMA Youth Members with scholarships to ... AMA Scholarship Program has awarded nearly $900,000 to college-bound ... model aviation organizations and individuals, AMA member donations, a ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Academy of Model Aeronautics Awards $46,500 in Scholarships to College-Bound Model Aviation Pilots 2
... ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today,announced ... that showed its,delivery technology, TPM, delivered leading pain-relief ... irritation of any kind., These results support ... a sustained release oxycodone patch for the management ...
... 17 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... a,leading European pharmaceutical and medical devices company, ... Vasogen,s Celacade(TM) System,in Germany. Celacade, a first-in-class ... that specifically targets the destructive chronic,inflammation underlying ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced ... Board of Directors. Mr. Turner brings over 25 years ... serve on,the company,s audit committee., "We are delighted ... S.,Henney, Chairman of the Board of Directors of SGX. ...
Cached Biology Technology:Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 2Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 2Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 4Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 5SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) ... Recognition Market by Solution, by Software, by Hardware, ... report to their offering. The ... become more efficient and cost effective. This has ... from the commercial sector. The development of 3D ...
(Date:5/28/2015)... , May 28, 2015 Industry ... of a new report titled "Markets for Self-Healing ... polymers, inorganic capsule and vascular systems, biomaterials, relevant ... grow to around $2.7 billion by 2020. ... n-tech,s extensive coverage of smart materials. Other recent n-tech ...
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... is used to soothe every kind of pain, from simple ... is one of the most used nowadays. However, research carried ... University of Granada showed that taking paracetamol slows ... studies. Author of this work is Olga Garca Mart ...
... VIEW, Calif., Aug. 13 LaserCard,Corporation (Nasdaq: ... credentials,used in biometric identification, today announced the expansion ... Eastern government. A new centralized high-volume card ... optical memory and the eye-readable data of,this state-of-the-art ...
... deepens customer relationships, WALL, N.J., Aug. 15 ... leader in wireless public safety and,finger-based biometric identification ... quarter ended June 30, 2007. Total revenue ... 30, 2007 decreased 19% to $2.5 million from ...
Cached Biology News:Paracetamol, one of most used analgesics, could slow down bone growth 2LaserCard Corporation Announces Expansion of Middle East Project 2LaserCard Corporation Announces Expansion of Middle East Project 3BIO-key Reports Second Quarter 2007 Results 2BIO-key Reports Second Quarter 2007 Results 3BIO-key Reports Second Quarter 2007 Results 4BIO-key Reports Second Quarter 2007 Results 5
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
... These handy dispensers save space ... hats, and other garb. They are ... small parts used in labs, processing ... static charges and the particles they ...
... production by luciferase-cDNA transfected cell lines has ... the development of reporter gene assays in ... indicator for the transcription of other genes. ... due to advantages such as high sensitivity ...
... Thermostable dUTPase The ... of high-fidelity PCR (using proofreading DNA ... present in PCR reactions and dNTP ... in a proofreading DNA polymerase reaction ...
Biology Products: